Jeffrey Cohen, MD

February 24, 2022

The professor of neurology at Cleveland Clinic and president of ACTRIMS noted his excitement for this year’s Forum, which will feature presentations on a variety of topics in the field of multiple sclerosis. [WATCH TIME: 2 minutes]

February 11, 2022

Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]

November 29, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the possibility of using multiple DMTs to combat the effects of MS. [WATCH TIME: 3 minutes]

November 22, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]

October 21, 2021

Ahmed Obeidat, MD, PhD; Jeffrey Cohen, MD; and Erin Longbrake, MD, PhD discuss the evolution of fellowship training for multiple sclerosis specialists.

October 14, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic provided context on whether efficacy outcomes should be weighed more than mechanistic action when evaluating MSC-NTF cell therapies. [WATCH TIME: 3 minutes]

October 13, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the use of MSC-NTF cells in progressive MS and the data backing this approach. [WATCH TIME: 3 minutes]

March 22, 2021

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

March 05, 2021

The president of the Americas Committee for Treatment and Research in MS discusses his takeaways from this year’s virtual forum.

July 27, 2020

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the benefit that physicians and patients can be provided by highly selective S1P modulators in MS treatment.